Acrivon Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Acrivon Therapeutics, Inc. (ACRV) reported Basic Shares Outstanding (Weighted Average) of 41.84 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- Acrivon Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 41.84M shares, a 8.79% increase year-over-year.
- Acrivon Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 38.72M shares, a 0.98% increase year-over-year.
- Acrivon Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 38.66M shares, a 1.01% increase year-over-year.
- Acrivon Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 38.56M shares, a 1.19% increase year-over-year.
- Acrivon Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 38.51M shares, a 13.96% increase from fiscal 2024.
- Acrivon Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 33.79M shares, a 53.06% increase from fiscal 2023.
- Acrivon Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 22.08M shares, a 435.63% increase from fiscal 2022.
- Acrivon Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 4.12M shares, a 136.43% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 41.84M shares 10-Q · filed 2026-08-12 | 40.29M shares 10-Q · filed 2026-08-12 | 39.74M shares derived: average of 3 quarters · filed 2026-08-12 | 39.45M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 38.72M shares 10-Q · filed 2026-05-13 | 38.69M shares derived: average of 2 quarters · filed 2026-05-13 | 38.65M shares derived: average of 3 quarters · filed 2026-05-13 | 38.60M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 38.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 38.61M shares derived: average of 2 quarters · filed 2026-03-19 | 38.56M shares derived: average of 3 quarters · filed 2026-08-12 | 38.51M shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 38.56M shares 10-Q · filed 2025-11-13 | 38.51M shares derived: average of 2 quarters · filed 2026-08-12 | 38.46M shares 10-Q · filed 2025-11-13 | 38.41M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 38.46M shares 10-Q · filed 2026-08-12 | 38.41M shares 10-Q · filed 2026-08-12 | 38.36M shares derived: average of 3 quarters · filed 2026-08-12 | 38.30M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 38.35M shares 10-Q · filed 2026-05-13 | 38.31M shares derived: average of 2 quarters · filed 2026-05-13 | 38.24M shares derived: average of 3 quarters · filed 2026-05-13 | 37.72M shares derived: average of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | 38.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 38.19M shares derived: average of 2 quarters · filed 2026-03-19 | 37.50M shares derived: average of 3 quarters · filed 2026-03-19 | 33.79M shares 10-K · filed 2026-03-19 |
| 2024-09-30 | 38.11M shares 10-Q · filed 2025-11-13 | 37.12M shares derived: average of 2 quarters · filed 2025-11-13 | 32.30M shares 10-Q · filed 2025-11-13 | 29.79M shares derived: average of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 36.13M shares 10-Q · filed 2025-08-13 | 29.36M shares 10-Q · filed 2025-08-13 | 27.02M shares derived: average of 3 quarters · filed 2025-08-13 | 25.79M shares derived: average of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | 22.59M shares 10-Q · filed 2025-05-14 | 22.46M shares derived: average of 2 quarters · filed 2025-05-14 | 22.34M shares derived: average of 3 quarters · filed 2025-05-14 | 22.25M shares derived: average of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | 22.34M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 22.21M shares derived: average of 2 quarters · filed 2025-03-27 | 22.13M shares derived: average of 3 quarters · filed 2025-03-27 | 22.08M shares 10-K · filed 2025-03-27 |
| 2023-09-30 | 22.08M shares 10-Q · filed 2024-11-13 | 22.03M shares derived: average of 2 quarters · filed 2024-11-13 | 21.99M shares 10-Q · filed 2024-11-13 | 19.29M shares derived: average of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | 21.97M shares 10-Q · filed 2024-08-13 | 21.95M shares 10-Q · filed 2024-08-13 | 18.35M shares derived: average of 3 quarters · filed 2024-08-13 | 14.21M shares derived: average of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | 21.92M shares 10-Q · filed 2024-05-14 | 16.55M shares derived: average of 2 quarters · filed 2024-05-14 | 11.62M shares derived: average of 3 quarters · filed 2024-05-14 | 9.16M shares derived: average of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | 11.17M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 6.47M shares derived: average of 2 quarters · filed 2024-03-28 | 4.91M shares derived: average of 3 quarters · filed 2024-03-28 | 4.12M shares 10-K · filed 2024-03-28 |
| 2022-09-30 | 1.78M shares 10-Q · filed 2023-11-09 | 1.77M shares derived: average of 2 quarters · filed 2023-11-09 | 1.77M shares 10-Q · filed 2023-11-09 | 1.77M shares derived: average of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 1.77M shares 10-Q · filed 2023-08-11 | 1.77M shares 10-Q · filed 2023-08-11 | 1.77M shares derived: average of 3 quarters · filed 2023-08-11 | 1.77M shares derived: average of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | 1.77M shares 10-Q · filed 2023-05-09 | 1.77M shares derived: average of 2 quarters · filed 2023-05-09 | 1.77M shares derived: average of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | 1.77M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | 1.77M shares derived: average of 2 quarters · filed 2023-03-28 | 1.74M shares 10-K · filed 2023-03-28 | |
| 2021-09-30 | 1.77M shares 10-Q · filed 2022-12-15 | 1.73M shares 10-Q · filed 2022-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |